EntryPoint Capital LLC Acquires New Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

EntryPoint Capital LLC bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 6,939 shares of the biopharmaceutical company’s stock, valued at approximately $292,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Smartleaf Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $42,000. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $43,000. Van ECK Associates Corp raised its position in shares of Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity

In related news, EVP Thomas Richard Kassberg sold 6,028 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the transaction, the executive vice president now owns 265,238 shares of the company’s stock, valued at approximately $11,166,519.80. This represents a 2.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Theodore Alan Huizenga sold 967 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now directly owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,370 shares of company stock valued at $5,751,499 in the last 90 days. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $38.89 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $36.71 and a one year high of $60.37. The stock has a fifty day moving average of $41.68 and a 200 day moving average of $47.03. The stock has a market cap of $3.60 billion, a PE ratio of -6.13 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Wedbush reissued a “neutral” rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $92.79.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.